Jordan, Olivier

Link to this page

Authority KeyName Variants
dd18ef71-ece7-405d-b16a-802332ad7db3
  • Jordan, Olivier (3)
Projects

Author's Bibliography

Sizing up the nanomedicines: a thorough examination of techniques and data interpretation

Nikolić, Ines; Đoković, Jelena; Mehn, Dora; Guerrini, Giuditta; Colpo, Pascal; Jordan, Olivier; Savić, Snežana; Borchard, Gerrit

(French Society for Nanomedicine (SFNano), 2023)

TY  - CONF
AU  - Nikolić, Ines
AU  - Đoković, Jelena
AU  - Mehn, Dora
AU  - Guerrini, Giuditta
AU  - Colpo, Pascal
AU  - Jordan, Olivier
AU  - Savić, Snežana
AU  - Borchard, Gerrit
PY  - 2023
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/5427
AB  - Size is a universal and first in mind property relevant for nanomedicine/nanomaterial
characterization, representing the most suitable measurand. However, due to the acknowledged
lack of standardized protocols that are able to provide reliable results, especially in the
biorelevant context, researchers often engage with the procedures that are successful in
acquiring data, but not necessarily the correct ones. ...
PB  - French Society for Nanomedicine (SFNano)
C3  - 9th SFNano annual meeting; December 4th - 6th, Montpellier, France
T1  - Sizing up the nanomedicines: a thorough examination of techniques and data interpretation
UR  - https://hdl.handle.net/21.15107/rcub_farfar_5427
ER  - 
@conference{
author = "Nikolić, Ines and Đoković, Jelena and Mehn, Dora and Guerrini, Giuditta and Colpo, Pascal and Jordan, Olivier and Savić, Snežana and Borchard, Gerrit",
year = "2023",
abstract = "Size is a universal and first in mind property relevant for nanomedicine/nanomaterial
characterization, representing the most suitable measurand. However, due to the acknowledged
lack of standardized protocols that are able to provide reliable results, especially in the
biorelevant context, researchers often engage with the procedures that are successful in
acquiring data, but not necessarily the correct ones. ...",
publisher = "French Society for Nanomedicine (SFNano)",
journal = "9th SFNano annual meeting; December 4th - 6th, Montpellier, France",
title = "Sizing up the nanomedicines: a thorough examination of techniques and data interpretation",
url = "https://hdl.handle.net/21.15107/rcub_farfar_5427"
}
Nikolić, I., Đoković, J., Mehn, D., Guerrini, G., Colpo, P., Jordan, O., Savić, S.,& Borchard, G.. (2023). Sizing up the nanomedicines: a thorough examination of techniques and data interpretation. in 9th SFNano annual meeting; December 4th - 6th, Montpellier, France
French Society for Nanomedicine (SFNano)..
https://hdl.handle.net/21.15107/rcub_farfar_5427
Nikolić I, Đoković J, Mehn D, Guerrini G, Colpo P, Jordan O, Savić S, Borchard G. Sizing up the nanomedicines: a thorough examination of techniques and data interpretation. in 9th SFNano annual meeting; December 4th - 6th, Montpellier, France. 2023;.
https://hdl.handle.net/21.15107/rcub_farfar_5427 .
Nikolić, Ines, Đoković, Jelena, Mehn, Dora, Guerrini, Giuditta, Colpo, Pascal, Jordan, Olivier, Savić, Snežana, Borchard, Gerrit, "Sizing up the nanomedicines: a thorough examination of techniques and data interpretation" in 9th SFNano annual meeting; December 4th - 6th, Montpellier, France (2023),
https://hdl.handle.net/21.15107/rcub_farfar_5427 .

The Landscape of Nanomedicines: An Expert Perspective

Nikolić, Ines; Filipić, Brankica; Marija Petrović; Jordan, Olivier; Savić, Snežana; Borchard, Gerrit

(Savez farmaceutskih udruženja Srbije, 2023)

TY  - JOUR
AU  - Nikolić, Ines
AU  - Filipić, Brankica
AU  - Marija Petrović
AU  - Jordan, Olivier
AU  - Savić, Snežana
AU  - Borchard, Gerrit
PY  - 2023
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/5358
AB  - The field of nanotechnology is at the forefront of a scientific revolution, where the term
“nano” transcends mere size and opens the door to enormous possibilities.
In the context of drug development, the selection of a suitable drug delivery system
(corresponding to a certain active pharmaceutical ingredient) is a pivotal decision. Accordingly,
nanosystems have emerged as a promising avenue, offering innovative solutions, and gaining
recognition for addressing healthcare issues.
While these products hold immense promise, they have faced certain complexities in their
translation from the preclinical to the clinical setting, reflected in the lack of proper assessment
protocols for quality and safety aspects and, consequently, an insufficiently defined regulatory
environment. Since the groundbreaking US Food and Drug Administration (FDA) approval of
liposomal doxorubicin in 1995, approximately 80 nanomedicine products have received regulatory
approval so far. Recent attention has gravitated toward lipid-based nanomedicines, particularly in
the development of mRNA vaccines during the COVID-19 pandemic, further highlighting their
significance. However, the relatively modest number of approved nanomedicines compared to the
extensive research efforts raises important questions and underscores areas of uncertainty.
This article provides an overview of the challenges in defining nanomedicines, their
properties, the complexities of regulatory frameworks, and the imperative for standardized
characterization protocols.
AB  - Polje nanotehnologije se nalazi na čelu naučne revolucije, gde se termin "nano" izdiže iznad pukog označavanja veličine, otvarajući vrata novim mogućnostima. U kontekstu razvoja lekova, izbor odgovarajućeg sistema za isporuku / nosača (koji odgovara određenoj aktivnoj supstanci) predstavlja ključnu odluku. U tom kontekstu, nanosistemi već određeno vreme predstavljaju inovativna rešenja. Iako farmaceutski nanosistemi nose ogroman potencijal, suočavaju se sa određenim izazovima u pogledu translacije sa prekliničkog na klinički nivo, što se ogleda u nedostatku odgovarajućih protokola za ispitivanje kvaliteta i bezbednosti i, shodno tome, nedefinisanom regulatornom okruženju. Od revolucionarnog odobrenja liposomalnog doksorubicina od strane Američke agencije za hranu i lekove 1995. godine, pa sve do danas, oko 80 nano formulacija (nanolekova) odobreno je za kliničku primenu. Odnedavno je intenzivnija pažnja usmerena ka nanoformulacijama baziranim na lipidima, što je delom posledica razvoja mRNK vakcina tokom pandemije COVID-19. Međutim, relativno skroman nastup nanolekova na tržištu (u poređenju sa obimnim istraživačkim naporima i finansijskim ulaganjima u ovu oblast) otvara važna pitanja. Ovaj rad pruža pregled izazova u definisanju nanolekova, njihovih svojstava, kompleksnosti regulatornih okvira i imperativa za stvaranje standardizovanih protokola karakterizacije.
PB  - Savez farmaceutskih udruženja Srbije
T2  - Arhiv za farmaciju
T1  - The Landscape of Nanomedicines: An Expert Perspective
T1  - "Pejzažni" prikaz nanolekova - ekspertska perspektiva
VL  - 73
IS  - 5
SP  - 390
EP  - 403
DO  - 10.5937/arhfarm73-46686
ER  - 
@article{
author = "Nikolić, Ines and Filipić, Brankica and Marija Petrović and Jordan, Olivier and Savić, Snežana and Borchard, Gerrit",
year = "2023",
abstract = "The field of nanotechnology is at the forefront of a scientific revolution, where the term
“nano” transcends mere size and opens the door to enormous possibilities.
In the context of drug development, the selection of a suitable drug delivery system
(corresponding to a certain active pharmaceutical ingredient) is a pivotal decision. Accordingly,
nanosystems have emerged as a promising avenue, offering innovative solutions, and gaining
recognition for addressing healthcare issues.
While these products hold immense promise, they have faced certain complexities in their
translation from the preclinical to the clinical setting, reflected in the lack of proper assessment
protocols for quality and safety aspects and, consequently, an insufficiently defined regulatory
environment. Since the groundbreaking US Food and Drug Administration (FDA) approval of
liposomal doxorubicin in 1995, approximately 80 nanomedicine products have received regulatory
approval so far. Recent attention has gravitated toward lipid-based nanomedicines, particularly in
the development of mRNA vaccines during the COVID-19 pandemic, further highlighting their
significance. However, the relatively modest number of approved nanomedicines compared to the
extensive research efforts raises important questions and underscores areas of uncertainty.
This article provides an overview of the challenges in defining nanomedicines, their
properties, the complexities of regulatory frameworks, and the imperative for standardized
characterization protocols., Polje nanotehnologije se nalazi na čelu naučne revolucije, gde se termin "nano" izdiže iznad pukog označavanja veličine, otvarajući vrata novim mogućnostima. U kontekstu razvoja lekova, izbor odgovarajućeg sistema za isporuku / nosača (koji odgovara određenoj aktivnoj supstanci) predstavlja ključnu odluku. U tom kontekstu, nanosistemi već određeno vreme predstavljaju inovativna rešenja. Iako farmaceutski nanosistemi nose ogroman potencijal, suočavaju se sa određenim izazovima u pogledu translacije sa prekliničkog na klinički nivo, što se ogleda u nedostatku odgovarajućih protokola za ispitivanje kvaliteta i bezbednosti i, shodno tome, nedefinisanom regulatornom okruženju. Od revolucionarnog odobrenja liposomalnog doksorubicina od strane Američke agencije za hranu i lekove 1995. godine, pa sve do danas, oko 80 nano formulacija (nanolekova) odobreno je za kliničku primenu. Odnedavno je intenzivnija pažnja usmerena ka nanoformulacijama baziranim na lipidima, što je delom posledica razvoja mRNK vakcina tokom pandemije COVID-19. Međutim, relativno skroman nastup nanolekova na tržištu (u poređenju sa obimnim istraživačkim naporima i finansijskim ulaganjima u ovu oblast) otvara važna pitanja. Ovaj rad pruža pregled izazova u definisanju nanolekova, njihovih svojstava, kompleksnosti regulatornih okvira i imperativa za stvaranje standardizovanih protokola karakterizacije.",
publisher = "Savez farmaceutskih udruženja Srbije",
journal = "Arhiv za farmaciju",
title = "The Landscape of Nanomedicines: An Expert Perspective, "Pejzažni" prikaz nanolekova - ekspertska perspektiva",
volume = "73",
number = "5",
pages = "390-403",
doi = "10.5937/arhfarm73-46686"
}
Nikolić, I., Filipić, B., Marija Petrović, Jordan, O., Savić, S.,& Borchard, G.. (2023). The Landscape of Nanomedicines: An Expert Perspective. in Arhiv za farmaciju
Savez farmaceutskih udruženja Srbije., 73(5), 390-403.
https://doi.org/10.5937/arhfarm73-46686
Nikolić I, Filipić B, Marija Petrović, Jordan O, Savić S, Borchard G. The Landscape of Nanomedicines: An Expert Perspective. in Arhiv za farmaciju. 2023;73(5):390-403.
doi:10.5937/arhfarm73-46686 .
Nikolić, Ines, Filipić, Brankica, Marija Petrović, Jordan, Olivier, Savić, Snežana, Borchard, Gerrit, "The Landscape of Nanomedicines: An Expert Perspective" in Arhiv za farmaciju, 73, no. 5 (2023):390-403,
https://doi.org/10.5937/arhfarm73-46686 . .

Sizing experiments and bio-nano interactions: method matters

Nikolić, Ines; Petrović, Marija; Krupnik, Leondard; Ranđelović, Danijela; Avaro, Jonathan; Neels, Antonia; Borchard, Gerrit; Jordan, Olivier; Đoković, Jelena; Savić, Snežana

(2023)

TY  - CONF
AU  - Nikolić, Ines
AU  - Petrović, Marija
AU  - Krupnik, Leondard
AU  - Ranđelović, Danijela
AU  - Avaro, Jonathan
AU  - Neels, Antonia
AU  - Borchard, Gerrit
AU  - Jordan, Olivier
AU  - Đoković, Jelena
AU  - Savić, Snežana
PY  - 2023
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/4571
AB  - INTRODUCTION
Physicochemical properties of many active ingredients jeopardize their pharmacological activity. To overcome identified obstacles, nanosystems as carriers for delivery of actives have been recognized as promising tools. Increasing number of applications for registration of nanotechnology-enabled pharmaceuticals and many more currently in preclinical or clinical studies raised some questions not only in the field of research and development, but also for regulators. Given the complexity of nanosystems, some specific challenges have been encountered in their characterization, which have not been fully addressed despite respectable research tradition in this field.  Particle size and aggregation potential (especially in complex biological fluids) are some of the critical quality attributes of nanomedicines, being important in the context of physical stability of the colloidal system, and in terms of its safety profile and in vivo performance. Even though a bright future has been predicted for nanomedicines, some of the posted expectations have not been fully met so far. This might be reflected, at least at some points, in the certain methodological issues that commonly result in in vitro to in vivo translational gaps. This aspect underlines the importance of quality and safety assessment of nanomedicines which has also been recognized by globally leading research and regulatory bodies [1,2]. Therefore, the aim of the presented research was to perform a thorough analysis of the selected nanosystem (nanoemulsion) focusing on size estimation and particle-protein interaction applying several techniques, highlighting important factors for a reliable analysis.
METHODLOGY
Materials
As a model nanosystem, previously developed nanoemulsion was used, containing medium-chain triglycerides (Mygliol 812, Fagron) as the oil phase, combination of polysorbate 80 (Acros Organics) and soybean lecithin (Lipoid S-75, Lipoid) as stabilizes, and highly purified water as the water phase. For protein interaction assessment, human serum albumin was used (HSA, Sigma Aldrich).
Methods
Nanoemulsion preparation
Nanoemulsion was prepared via spontaneous emulsification, by dropwise addition of the mixture of the oil and stabilizers to the water phase under constant stirring. For nanoparticle-protein interaction assesment, nanoemulsion was incubated (1h, 37 °C) with HSA in the final concentration of 2.5 mg/ml. 
Sizing experiments – dynamic light scattering
Size and size distribution (per se and in biorelevant environment) were evaluated applying batch mode dynamic light scattering (DLS, Zetasizer Nano ZS90, Malvern Instruments, UK), following the NCL guidance [3]. Intensity-based average hydrodynamic diameter (Z-ave) and polydispersity index (PDI) were analysed in line with relevant parameters of the method. 
Atomic force microscopy (AFM)
Additional sizing analysis and morphological evaluation of the sample were performed applying AFM as a high-resolution technique. AFM analysis of the samples was performed by NTEGRA Prima atomic force microscope (NT-MDT, Moscow, Russia). Intermittent-contact AFM mode was applied using NT-MDT NSGO1 silicon, N-type, antimony doped cantilevers with Au reflective coating. Sample dilution corresponded to the optimal one selected for DLS, and 10 μl of the dilution was placed to the high-quality silica discs (Highest Grade V1 Mica Discs, Ted Pella Inc.) and dried in vacuum. Experiments were performed in the air, in contactless mode. Topographic images and “signal-error” images were collected, AFM images were created and analyzed with the software Image Analysis 2.2.0 (NT-MDT) and Gwyddion 2.60 (Free and Open Source software, Department of Nanometrology, Czech Metrology Institute).
Small angle X-ray scattering (SAXS)
SAXS experiments were performed with the general idea to analyze the structure of the dispersed nanodroplets more profoundly, and especially interactions in biorelevant surrounding (in contact with HSA). A laboratory X-ray setup was applied (Bruker Nanostar, Bruker AXS GmbH, Karlsruhe, Germany). Here, the Kα-line of a X-ray Cu source with a wavelength of 1.541 Å was used and further monochromated by a X-ray mirror. The beam was collimated to a beam diameter of approximately 0.4 mm using three pinholes. The sample-detector distance was set to 107 cm, which lead to a q-range of 0.07 ≤ q ≤ 2.3 nm-1. Calibration of the scattering vector q and estimation of the instrumental resolution of Δq = 0.25 nm-1 was done by measuring the first diffraction peak of a silver behenate sample. The scattered intensity was measured with an avalanche-based detector (VÅNTEC-2000, Bruker AXS). The transmitted part of the beam was determined using a home-made semi-transparent beam stop. The scattered intensity was extracted, radially averaged and integrated over all q-values using the Bruker software DIF-FRAC.EVA (Bruker AXS, version 4.1). The 1D data was transmission corrected and then background subtracted from the scattering of the solvent and the capillary using Matlab 2022.
RESULTS AND DISCUSSION
When applying DLS, as a preliminary technique, primary attention was put on the selection of optimal dilution level for the measurement, analyzing attenuation factor, count rate and intercept of the correlation function in different dilution ratios and with different dilution media (water, PBS 7.4 and 10 mM NaCl), and dilution 1:100 (v/v) was marked as the optimal one. However, significant differences in obtained nanodroplet size was observed depending on the type of medium. When water was used as a dilution medium, significantly higher Z-ave values were obtained (83.71±0.86 nm) compared to the situations where PBS 7.4 (73.50±0.75nm) or 10 mM NaCl (76.59±0.50nm) were used as dilution medium, indicating how sample preparation protocol might be crucial. Even though DLS was not sensitive enough to detect any interaction with HSA (no significant difference in terms of Z-ave and PDI compared to the results obtained in the same dilution medium without HSA), AFM captured qualitative difference in the droplet topography (Figure 1), raising ides on nanoemulsion interfacial interaction with HSA and increased aggregation potential. Further on, SAXS confirmed the existence of a bilayer structure as indicated by a prominent correlation peak at around 1 nm-1, which corresponds to a bilayer thickness of around 6.2 nm. SAXS (Figure 2; probably corresponding to the lecithin formations at the interface). It may be assumed that the bilayer structure changes its structure when mixed with HSA. 
CONCLUSION
In this research, it has been demonstrated how important is to carefully select measurement conditions even for DLS -commonly used and the only standardized methods, in order to keep the measurements meaningful. Further on, not every method is capable of detecting some specific bio-nano interactions. Aiming to generate reliable datasets, condition sine qua non is to perform complementary techniques with increasing complexity. Further experimental segments should cover additional evaluation (e.g. analytical ultracentrifugation, thermal analysis, interfacial properties assessment, electron microscopy) that would shed light on bio-nano interactions important for in vivo fate of the nanosystems.
C3  - 4th European Conference on Pharmaceutics, 20 - 21 March 2023, Marseille, France
T1  - Sizing experiments and bio-nano interactions: method matters
UR  - https://hdl.handle.net/21.15107/rcub_farfar_4571
ER  - 
@conference{
author = "Nikolić, Ines and Petrović, Marija and Krupnik, Leondard and Ranđelović, Danijela and Avaro, Jonathan and Neels, Antonia and Borchard, Gerrit and Jordan, Olivier and Đoković, Jelena and Savić, Snežana",
year = "2023",
abstract = "INTRODUCTION
Physicochemical properties of many active ingredients jeopardize their pharmacological activity. To overcome identified obstacles, nanosystems as carriers for delivery of actives have been recognized as promising tools. Increasing number of applications for registration of nanotechnology-enabled pharmaceuticals and many more currently in preclinical or clinical studies raised some questions not only in the field of research and development, but also for regulators. Given the complexity of nanosystems, some specific challenges have been encountered in their characterization, which have not been fully addressed despite respectable research tradition in this field.  Particle size and aggregation potential (especially in complex biological fluids) are some of the critical quality attributes of nanomedicines, being important in the context of physical stability of the colloidal system, and in terms of its safety profile and in vivo performance. Even though a bright future has been predicted for nanomedicines, some of the posted expectations have not been fully met so far. This might be reflected, at least at some points, in the certain methodological issues that commonly result in in vitro to in vivo translational gaps. This aspect underlines the importance of quality and safety assessment of nanomedicines which has also been recognized by globally leading research and regulatory bodies [1,2]. Therefore, the aim of the presented research was to perform a thorough analysis of the selected nanosystem (nanoemulsion) focusing on size estimation and particle-protein interaction applying several techniques, highlighting important factors for a reliable analysis.
METHODLOGY
Materials
As a model nanosystem, previously developed nanoemulsion was used, containing medium-chain triglycerides (Mygliol 812, Fagron) as the oil phase, combination of polysorbate 80 (Acros Organics) and soybean lecithin (Lipoid S-75, Lipoid) as stabilizes, and highly purified water as the water phase. For protein interaction assessment, human serum albumin was used (HSA, Sigma Aldrich).
Methods
Nanoemulsion preparation
Nanoemulsion was prepared via spontaneous emulsification, by dropwise addition of the mixture of the oil and stabilizers to the water phase under constant stirring. For nanoparticle-protein interaction assesment, nanoemulsion was incubated (1h, 37 °C) with HSA in the final concentration of 2.5 mg/ml. 
Sizing experiments – dynamic light scattering
Size and size distribution (per se and in biorelevant environment) were evaluated applying batch mode dynamic light scattering (DLS, Zetasizer Nano ZS90, Malvern Instruments, UK), following the NCL guidance [3]. Intensity-based average hydrodynamic diameter (Z-ave) and polydispersity index (PDI) were analysed in line with relevant parameters of the method. 
Atomic force microscopy (AFM)
Additional sizing analysis and morphological evaluation of the sample were performed applying AFM as a high-resolution technique. AFM analysis of the samples was performed by NTEGRA Prima atomic force microscope (NT-MDT, Moscow, Russia). Intermittent-contact AFM mode was applied using NT-MDT NSGO1 silicon, N-type, antimony doped cantilevers with Au reflective coating. Sample dilution corresponded to the optimal one selected for DLS, and 10 μl of the dilution was placed to the high-quality silica discs (Highest Grade V1 Mica Discs, Ted Pella Inc.) and dried in vacuum. Experiments were performed in the air, in contactless mode. Topographic images and “signal-error” images were collected, AFM images were created and analyzed with the software Image Analysis 2.2.0 (NT-MDT) and Gwyddion 2.60 (Free and Open Source software, Department of Nanometrology, Czech Metrology Institute).
Small angle X-ray scattering (SAXS)
SAXS experiments were performed with the general idea to analyze the structure of the dispersed nanodroplets more profoundly, and especially interactions in biorelevant surrounding (in contact with HSA). A laboratory X-ray setup was applied (Bruker Nanostar, Bruker AXS GmbH, Karlsruhe, Germany). Here, the Kα-line of a X-ray Cu source with a wavelength of 1.541 Å was used and further monochromated by a X-ray mirror. The beam was collimated to a beam diameter of approximately 0.4 mm using three pinholes. The sample-detector distance was set to 107 cm, which lead to a q-range of 0.07 ≤ q ≤ 2.3 nm-1. Calibration of the scattering vector q and estimation of the instrumental resolution of Δq = 0.25 nm-1 was done by measuring the first diffraction peak of a silver behenate sample. The scattered intensity was measured with an avalanche-based detector (VÅNTEC-2000, Bruker AXS). The transmitted part of the beam was determined using a home-made semi-transparent beam stop. The scattered intensity was extracted, radially averaged and integrated over all q-values using the Bruker software DIF-FRAC.EVA (Bruker AXS, version 4.1). The 1D data was transmission corrected and then background subtracted from the scattering of the solvent and the capillary using Matlab 2022.
RESULTS AND DISCUSSION
When applying DLS, as a preliminary technique, primary attention was put on the selection of optimal dilution level for the measurement, analyzing attenuation factor, count rate and intercept of the correlation function in different dilution ratios and with different dilution media (water, PBS 7.4 and 10 mM NaCl), and dilution 1:100 (v/v) was marked as the optimal one. However, significant differences in obtained nanodroplet size was observed depending on the type of medium. When water was used as a dilution medium, significantly higher Z-ave values were obtained (83.71±0.86 nm) compared to the situations where PBS 7.4 (73.50±0.75nm) or 10 mM NaCl (76.59±0.50nm) were used as dilution medium, indicating how sample preparation protocol might be crucial. Even though DLS was not sensitive enough to detect any interaction with HSA (no significant difference in terms of Z-ave and PDI compared to the results obtained in the same dilution medium without HSA), AFM captured qualitative difference in the droplet topography (Figure 1), raising ides on nanoemulsion interfacial interaction with HSA and increased aggregation potential. Further on, SAXS confirmed the existence of a bilayer structure as indicated by a prominent correlation peak at around 1 nm-1, which corresponds to a bilayer thickness of around 6.2 nm. SAXS (Figure 2; probably corresponding to the lecithin formations at the interface). It may be assumed that the bilayer structure changes its structure when mixed with HSA. 
CONCLUSION
In this research, it has been demonstrated how important is to carefully select measurement conditions even for DLS -commonly used and the only standardized methods, in order to keep the measurements meaningful. Further on, not every method is capable of detecting some specific bio-nano interactions. Aiming to generate reliable datasets, condition sine qua non is to perform complementary techniques with increasing complexity. Further experimental segments should cover additional evaluation (e.g. analytical ultracentrifugation, thermal analysis, interfacial properties assessment, electron microscopy) that would shed light on bio-nano interactions important for in vivo fate of the nanosystems.",
journal = "4th European Conference on Pharmaceutics, 20 - 21 March 2023, Marseille, France",
title = "Sizing experiments and bio-nano interactions: method matters",
url = "https://hdl.handle.net/21.15107/rcub_farfar_4571"
}
Nikolić, I., Petrović, M., Krupnik, L., Ranđelović, D., Avaro, J., Neels, A., Borchard, G., Jordan, O., Đoković, J.,& Savić, S.. (2023). Sizing experiments and bio-nano interactions: method matters. in 4th European Conference on Pharmaceutics, 20 - 21 March 2023, Marseille, France.
https://hdl.handle.net/21.15107/rcub_farfar_4571
Nikolić I, Petrović M, Krupnik L, Ranđelović D, Avaro J, Neels A, Borchard G, Jordan O, Đoković J, Savić S. Sizing experiments and bio-nano interactions: method matters. in 4th European Conference on Pharmaceutics, 20 - 21 March 2023, Marseille, France. 2023;.
https://hdl.handle.net/21.15107/rcub_farfar_4571 .
Nikolić, Ines, Petrović, Marija, Krupnik, Leondard, Ranđelović, Danijela, Avaro, Jonathan, Neels, Antonia, Borchard, Gerrit, Jordan, Olivier, Đoković, Jelena, Savić, Snežana, "Sizing experiments and bio-nano interactions: method matters" in 4th European Conference on Pharmaceutics, 20 - 21 March 2023, Marseille, France (2023),
https://hdl.handle.net/21.15107/rcub_farfar_4571 .